AI Verdict
RAMP has stronger fundamentals based on our AI analysis.
RAPH vs RAMP Fundamental Comparison
| Metric | RAPH | RAMP |
|---|---|---|
| Revenue | N/A | $606.8M |
| Net Income | $-1.3M | $75.0M |
| Net Margin | N/A | 12.4% |
| ROE | N/A | 7.8% |
| ROA | -2,413.2% | 5.9% |
| Current Ratio | 0.03x | 2.72x |
| Debt/Equity | N/A | 0.00x |
| EPS | $0.07 | $1.14 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RAPH vs RAMP: Frequently Asked Questions
Is RAPH or RAMP a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RAMP has stronger fundamentals. RAPH is rated STRONG SELL (90% confidence) while RAMP is rated HOLD (58% confidence). This is not investment advice.
How does RAPH compare to RAMP fundamentally?
Raphael Pharmaceutical Inc. has ROE of N/A vs LiveRamp Holdings, Inc.'s 7.8%. Net margins are N/A vs 12.4% respectively.
Which stock pays higher dividends, RAPH or RAMP?
RAPH has a dividend yield of N/A or no dividend while RAMP has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RAPH or RAMP for long term?
For long-term investing, consider that RAPH has STRONG SELL rating with 90% confidence, while RAMP has HOLD rating with 58% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RAPH vs RAMP?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RAPH vs RAMP, the AI consensus favors RAMP based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.